 |
|
Lack of motivation in schizophrenia linked to brain chemical imbalance
May 08, 2008A study of patients with psychotic illnesses such as schizophrenia suggests an alternative explanation for why many sufferers lack motivation. The research is described today BioMed Central's journal BMC Psychiatry.
In addition to the hallucinations that often characterize schizophrenia, patients also have major problems with apathy and lack of motivation. The dopamine hypothesis argues that unusual behaviour associated with schizophrenia can largely be explained by variations in the dopamine function of the brain. Exploring a possible link between dopamine activity and the lack of motivation could be key to developing new approaches to helping such patients cope with life.
In a study funded by the National Institute of Health Research, Dr Graham Murray of the Department of Psychiatry at the University of Cambridge and colleagues studied 18 patients presenting with first-episode psychotic symptoms. They compared the patients' performance against 19 healthy participants in a computerised test of motivated behaviour.
The participants took part in a reaction time test, assigning a reward to each trial. In the control group, almost all individuals reacted faster if the potential reward for completing the task was higher. This well documented phenomenon was observed in less than a quarter of the first-episode psychosis group, suggesting an abnormality in the processing of incentives for their actions. Eleven of these participants were taking atypical antipsychotic medications, which are sometimes thought to be responsible for 'demotivating' patients. However, this study found that these medications had no significant effect on the results.
In the past, some critics have suggested that patients' motivational problems are simply secondary to long-term treatment effects, or institutionalisation, but because the researchers studied young adults at the very early stages of their illness, they could rule out this possibility. "Patients with psychosis already have motivational deficits the first time they present to health services." said Dr Murray. "Understanding the brain basis of these problems will ultimately help in developing new treatments."
The next step in demonstrating a link between lack of motivation and the brain's biochemical reward system will be to investigate whether self-motivation can be safely stimulated in patients with psychoses using medication, including drugs that trigger the release of dopamine but which do not worsen their other symptoms.
BioMed Central
The participants took part in a reaction time test, assigning a reward to each trial. In the control group, almost all individuals reacted faster if the potential reward for completing the task was higher. This well documented phenomenon was observed in less than a quarter of the first-episode psychosis group, suggesting an abnormality in the processing of incentives for their actions. Eleven of these participants were taking atypical antipsychotic medications, which are sometimes thought to be responsible for 'demotivating' patients. However, this study found that these medications had no significant effect on the results.
In the past, some critics have suggested that patients' motivational problems are simply secondary to long-term treatment effects, or institutionalisation, but because the researchers studied young adults at the very early stages of their illness, they could rule out this possibility. "Patients with psychosis already have motivational deficits the first time they present to health services." said Dr Murray. "Understanding the brain basis of these problems will ultimately help in developing new treatments."
The next step in demonstrating a link between lack of motivation and the brain's biochemical reward system will be to investigate whether self-motivation can be safely stimulated in patients with psychoses using medication, including drugs that trigger the release of dopamine but which do not worsen their other symptoms.
BioMed Central
Schizophrenia News and Current Schizophrenia Events RSSHuman brains pay a price for being big
Metabolic changes responsible for the evolution of our unique cognitive abilities indicate that the brain may have been pushed to the limit of its capabilities. Research published today in BioMed Central's open access journal Genome Biology adds weight to the theory that schizophrenia is a costly by-product of human brain evolution.
Estrogen relieves psychotic symptoms in women with schizophrenia
When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.
Protein marker for schizophrenia risk
A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression
New findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated with many psychiatric illnesses, such as schizophrenia, bipolar disorder and depression.
A Computer That Can 'Read' Your Mind
For centuries, the concept of mind readers was strictly the domain of folklore and science fiction. But according to new research published today in the journal Science, scientists are closer to knowing how specific thoughts activate our brains. The findings demonstrate the power of computational modeling to improve our understanding of how the brain processes information and thoughts.
Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs
Researchers at Columbia University Medical Center have illuminated a window into how abnormalities in microRNAs, a family of molecules that regulate expression of numerous genes, may contribute to the behavioral and neuronal deficits associated with schizophrenia and possibly other brain disorders.
More Schizophrenia News Articles
 | The Soloist: A Lost Dream, an Unlikely Friendship, and the Redemptive Power of Music by Steve Lopez |
 | The Center Cannot Hold: My Journey Through Madness by Elyn R. Saks |
 | The Quiet Room: A Journey Out of the Torment of Madness by Lori Schiller, Amanda Bennett |
 | Gut and Psychology Syndrome: Natural Treatment for Autism,ADD/ADHD,Dyslexia,Dyspraxia,Depression,Schizophrenia by Dr. Natasha Campbell-McBride MD |
 | Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (4th Edition) by E. Fuller Torrey |
 | Abnormal Psychology (5th Edition) by Thomas F. Oltmanns, Robert E. Emery |
 | Nutrition and Mental Illness: An Orthomolecular Approach to Balancing Body Chemistry by Carl C. Pfeiffer |
 | Abnormal Psychology in a Changing World by Jeffrey S. Nevid, Spence A. Rathus, Beverly Greene |
 | A Thousand Plateaus: Capitalism and Schizophrenia by Gilles Deleuze, Felix Guattari, Brian Massumi |
 | Recovered, Not Cured: A Journey Through Schizophrenia by Richard McLean |
| © 2008 BrightSurf.com |